Compare Novavax Inc (NVAX) vs Quanta Services Inc (PWR) Price & Performance

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.

PWR trades at $672.78, up 0.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $28.48B in 2025, and the company raised its 2026 outlook, supported by record backlog and infrastructure demand. Analyst consensus is strongly bullish with a $809.75 price target.

The outlook is positive due to accelerating growth and raised guidance, but high valuation multiples (P/E 77.58) pose a risk. Key opportunities include AI-driven R&D expansion and power infrastructure projects, while execution delays and macroeconomic pressures are primary concerns for investors.